Less than half of respondents said they were working on modalities related to COVID-19.
Of those respondents, there was a fairly even split between those working with oligonucleotides, peptides and mRNA in relation to the virus, with peptides and mRNA being the most common. One respondent also said that they were working on conjugates related to COVID-19.
The most common COVID-19-related application that our respondents were working on was therapeutics, closely followed by vaccines.
Respondents focused on COVID-19-related therapeutics were from pharma, biotech, CRO and academic organizations, whereas COVID-19-related vaccines were being worked on by respondents from a wider variety of organizations including VCs and medical device firms. In the small proportion of respondents working on COVID-19-related diagnostics, the majority were from academic institutes.
As their biggest challenge within their COVID-19 research and development, respondents gave a wide variety of answers, including testing, capacity and time issues.
